Close Menu

NEW YORK – LexaGene said today that it has closed a previously announced financing round, grossing C$6.7 million (US$5.1 million).

The Beverly, Massachusetts-based firm, which trades on the Toronto Stock Exchange, will use the net proceeds for research and development, marketing, and general corporate purposes to support commercialization efforts of its LX Analyzer technology, which uses microfluidic PCR for pathogen detection. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.